Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMUNDSEN-real
2024-518195-31-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 4, randomised trial in myocardial infarction (MI) and Myocardial Infarction (MI) comparing Evolocumab plus standard-of-care lipid-lowering with Standard-of-care lipid-lowering alone (2 arms). Primary endpoints: Lipid primary endpoint, Lipid trajectory and 1 more. Planned start Sep 2021; status: authorised.
02
Drugs
evolocumab
03
Conditions
myocardial infarction (MI)Myocardial Infarction (MI)
Beyond the preview
Go deeper on 2024-518195-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518195-31-00.